FY2025 EPS Estimates for AVITA Medical Raised by Analyst

AVITA Medical, Inc. (NASDAQ:RCEL) – Investment analysts at Cantor Fitzgerald lifted their FY2025 earnings per share estimates for AVITA Medical in a research note issued to investors on Monday, May 12th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($0.99) per share for the year, up from their previous forecast of ($1.01). The consensus estimate for AVITA Medical’s current full-year earnings is ($0.95) per share.

AVITA Medical (NASDAQ:RCEL) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.14). AVITA Medical had a negative return on equity of 337.91% and a negative net margin of 96.26%. The business had revenue of $18.51 million during the quarter, compared to the consensus estimate of $33.15 million.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $22.00 price objective on shares of AVITA Medical in a report on Thursday, April 10th.

AVITA Medical Stock Performance

AVITA Medical stock opened at $7.01 on Wednesday. The company has a quick ratio of 2.47, a current ratio of 2.83 and a debt-to-equity ratio of 9.39. The company has a market capitalization of $185.31 million, a PE ratio of -2.93 and a beta of 1.74. The firm has a fifty day simple moving average of $8.81 and a two-hundred day simple moving average of $10.23. AVITA Medical has a twelve month low of $6.60 and a twelve month high of $14.16.

Insider Activity at AVITA Medical

In other news, Director Robert Mcnamara acquired 10,000 shares of the stock in a transaction dated Thursday, February 20th. The stock was purchased at an average cost of $10.09 per share, with a total value of $100,900.00. Following the completion of the purchase, the director now owns 45,749 shares in the company, valued at approximately $461,607.41. The trade was a 27.97% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.82% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Nuveen LLC purchased a new stake in AVITA Medical in the 1st quarter worth approximately $584,000. Evernest Financial Advisors LLC purchased a new position in AVITA Medical during the 1st quarter valued at $411,000. Meeder Asset Management Inc. bought a new position in AVITA Medical in the 1st quarter worth $53,000. CWM LLC lifted its position in shares of AVITA Medical by 1,099.5% in the 1st quarter. CWM LLC now owns 4,918 shares of the company’s stock worth $40,000 after purchasing an additional 4,508 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of AVITA Medical by 3.6% during the 1st quarter. Bank of New York Mellon Corp now owns 55,141 shares of the company’s stock valued at $449,000 after purchasing an additional 1,924 shares in the last quarter. Hedge funds and other institutional investors own 27.66% of the company’s stock.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.